PMC PharMerica Corporation

PharMerica Appoints Robert E. Dries as Executive Vice President and Chief Financial Officer

LOUISVILLE, Ky.--(BUSINESS WIRE)--

PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy, specialty infusion and hospital pharmacy management services, today announced the appointment of Robert E. Dries as Executive Vice President and Chief Financial Officer, effective January 31, 2017. Mr. Dries brings to PharMerica more than 25 years of financial and operational experience and a deep knowledge of the pharmacy services industry. From 1996 to 2016, Mr. Dries held several senior positions at Omnicare Inc., most recently serving as Senior Vice President, Financial Operations from 2012 to 2016. Mr. Dries began his career at KPMG, where he provided accounting, auditing and consulting services to both public and private companies.

Gregory S. Weishar, PharMerica’s Chief Executive Officer, said, “Bob brings extensive financial and operational knowledge, as well as significant experience in the pharmacy services industry. I am confident Bob’s proven leadership and ability to manage complex issues will help advance our growth strategies.”

“I am honored to be chosen as PharMerica’s CFO,” said Mr. Dries. “PharMerica has achieved impressive growth, and has a compelling acquisition pipeline to continue expanding its institutional and specialty pharmacy businesses. I look forward to working with the talented PharMerica team to drive sustainable shareholder value creation.”

About PharMerica

PharMerica Corporation is a leading provider of pharmacy services. PharMerica serves the long-term care, hospital pharmacy management services, specialty home infusion and oncology pharmacy markets. PharMerica operates 99 institutional pharmacies, 19 specialty home infusion pharmacies and 4 specialty oncology pharmacies in 45 states. PharMerica’s customers are institutional healthcare providers, such as skilled nursing facilities, assisted living facilities, hospitals, individuals receiving in-home care and patients with cancer.

EN
31/01/2017

Underlying

PMCPharMerica Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PharMerica Corporation

 PRESS RELEASE
Free
PMC PharMerica Corp...

KKR Completes Acquisition of PharMerica

LOUISVILLE, Ky.--(BUSINESS WIRE)-- PharMerica Corporation (NYSE:PMC) today announced the completion of the acquisition of PharMerica by a newly formed company controlled by KKR with an affiliate of Walgreens Boots Alliance, Inc. (Nasdaq: WBA) as a minority investor. As a result of the completion of the acquisition, PharMerica shareholders will receive an amount in cash equal to $29.25 per share of PharMerica common stock, without interest. In connection with the completion of the acquisition, shares of PharMerica’s common sto...

December 7, 2017 1 EN
 PRESS RELEASE
Free
PMC PharMerica Corp...

PharMerica Reports Third Quarter 2017 Results

LOUISVILLE, Ky.--(BUSINESS WIRE)-- PharMerica Corporation (NYSE: PMC), a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, today reported its financial results for the third quarter ended September 30, 2017. Third Quarter 2017 Results The results for the third quarter of 2017 are set forth below: Key Comparisons of Third Quarters Ended September 30, 2017 and 2016: Revenues for the third quarter of 2017 were $595.1...

November 9, 2017 1 EN
 PRESS RELEASE
Free
PMC PharMerica Corp...

PharMerica Announces Approval of Merger by Stockholders

LOUISVILLE, Ky.--(BUSINESS WIRE)-- PharMerica Corporation (NYSE: PMC), announced that at its special meeting of stockholders held today, a majority of the outstanding shares of PharMerica common stock voted to approve the adoption of the previously disclosed definitive merger agreement pursuant to which a newly formed company controlled by KKR, with Walgreens Boots Alliance, Inc. (Nasdaq: WBA) as a minority investor, will acquire PharMerica. The closing of the transaction remains subject to customary closing conditions. ...

November 9, 2017 1 EN
Free Trial
PMC PharMerica Corp...

PHARMERICA CORP. reduces its risk exposure and slightly improves to Ne...

The independent financial analyst theScreener just allocated a lower risk rating to PHARMERICA CORP. (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title still shows 3 out of 4 possible stars. Its market behaviour, however, has slightly improved and can be qualified as moderately risky. theScreener considers that these elements merit an overall rating upgrade to Neutral. As of the analysis date October 27, 2017, the closing price was USD 29.10 and i...

PMC PHARMERICA CORPORATION
10/28/17 October 28, 2017 6 EN
 PRESS RELEASE
Free
PMC PharMerica Corp...

Onco360 Selected for VERZENIO® Limited Distribution Pharmacy Network

LOUISVILLE, Ky.--(BUSINESS WIRE)-- Onco360, the nation’s largest independent Oncology Pharmacy, announced today that it has been selected to participate in the limited distribution network for Eli Lilly and Company’s new product, VERZENIOTM (Abemaciclib), a twice daily oral cyclin-dependent kinase (CDK) 4/6 inhibitor approved by the U.S. Food and Drug Administration (FDA). VERZENIO is used in combination with fulvestrant to treat women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanc...

October 16, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch